Posted On: 09/08/2014 12:19:10 AM
Post# of 30066
I do believe LymPro revenue will be a gradual winner for us in 2015. But the first half of 2015 might be slow. I hope Gerald isn't planning on using more dilution to get us through that period.
It sounds like we are voting on a billion extra authorized shares based on "hopes" of catalysts in the future. The MANF orphan designations might happen in December or Q1 of 2015, but they will not move our stock substantially! If all we have in Q1 2015 is some orphan designations but no partnerships and Lympro is taking time to ramp up revenue, I see substantial dilution.
We are paying for Eltoprazine trials and have increased our overhead substantially in the past 6 months. If J&J had dropped 40 million on us in a LymPro JV....no problem. We could buy Gerald a company jet too if that happened. But it didn't. And short of a surprise MANF partnership in the next 14 days, we will be voting on increasing our future potential dilution by a billion shares....based on future hopes.
I just think we need to cash in at least one of those hopes first....before we vote to dilute.
It sounds like we are voting on a billion extra authorized shares based on "hopes" of catalysts in the future. The MANF orphan designations might happen in December or Q1 of 2015, but they will not move our stock substantially! If all we have in Q1 2015 is some orphan designations but no partnerships and Lympro is taking time to ramp up revenue, I see substantial dilution.
We are paying for Eltoprazine trials and have increased our overhead substantially in the past 6 months. If J&J had dropped 40 million on us in a LymPro JV....no problem. We could buy Gerald a company jet too if that happened. But it didn't. And short of a surprise MANF partnership in the next 14 days, we will be voting on increasing our future potential dilution by a billion shares....based on future hopes.
I just think we need to cash in at least one of those hopes first....before we vote to dilute.
(0)
(0)
